Empowering the immune system to cure cancer and autoimmune disorders.
About us
Our vision
Cure
Our ambition is to provide patients suffering from hard-to-treat conditions a curative treatment option.
Care
Our priority is to provide safe treatment options to these patients in need.
Deliver
Collaborate
Cure
Our ambition is to provide patients suffering from hard-to-treat conditions a curative treatment option.
Care
Our priority is to provide safe treatment options to these patients in need.
Deliver
Collaborate
Our culture is to bring together diverse talents and energies to deliver on our ambitious objectives.
Our science
Unlocking the Full Potential of CAR-T therapies with In Vivo Engineering.
Our in vivo technology unlocks immune mechanisms inaccessible to ex vivo CAR-T, enabling potential deeper responses and broader patient access.
- Absence of lymphodepletion preserves the full immune compartment, enabling bystander immune cells (e.g. NK cells, dendritic cells and monocytes) to boost anti-tumour activity
- Our vectors not only generate CAR T cells in situ, but also CAR M cells to provide synergy between adaptive and innate immunity
- Off-the-shelf vector products with simpler manufacture compared to ex vivo CAR T cells
Harnessing innate-adaptive synergy to overcome the tumour microenvironment.
Thesian’s lentiviral vectors use an engineered fusogen to selectively target naïve and activated T cells, monocytes, and macrophages (M cells) in circulation and in the tumour microenvironment (TME), enabling direct in vivo delivery of therapeutic genes and generation of CAR-T and CAR-M cells inside the patient.
CAR-T cells provide potent cytotoxicity, while CAR-M cells convert immunosuppressive macrophages into pro-inflammatory effectors that remodel the TME through antigen spreading, phagocytosis, and immune-cell recruitment. Cytokine armouring can further amplify this local activation.
By harnessing this innate–adaptive synergy, the platform aims to achieve potent activity in hard-to-treat blood cancers and solid tumours traditionally resistant to treatment due to the TME.
The ARIANE platform
- Thesian’s AND-logic gates fusogen
Targets T & M cells
Prevents B-cell transduction & liver uptake
No exogenous binders nor T cell activation - Large potential of Cargos
Single or dual CARs, cytokines armoring - 3rd gen. LVV with high production titers
Integrating or non-integrating depending on the need for long term stable vector
Precision and safety through AND-logic gating
Our lentiviral vectors use a fusogen that requires two specific co-receptors on T and M cells to trigger fusion. This AND-logic design prevents transduction of off-target cells lacking either receptor, achieving complete liver detargeting and ensuring only the intended immune subsets receive the CAR payload.
Promoting a more physiological response
Many in vivo CAR-T approaches struggle to reach naïve/resting T cells and instead rely on activating binders that can overstimulate them. Because naïve/restingT cells, which represent 90-95 % of the T cell compartment, naturally express our LVV receptors, we efficiently deliver the CAR without artificial activation, supporting a more physiological and controlled immune response.
By combining selective targeting, innate-adaptive synergy, physiological immune activation, and modular design, the Ariane platform enables the development of precise and potent immune therapies that can reach more patients.
Our team
Thesian bio
Rémi Soula, PhD, MBA
CEO, Co-Founder
Oscar Castanon, PhD
Business Development Lead, Co-Founder
Yatish Lad, PhD
CSO
Rebecca Alade, MRes
Principal Scientist
Soha El Sayed, PhD
Scientific Project Manager
University Pompeu Fabra
Marc Güell, PhD
Main Researcher, Co-Founder
Dimitrije Ivancic, PhD
Post-Doctoral Researcher, Co-Founder
Cristina Rius Rafael, PhD
Post-Doctoral Researcher
We are always open to new talent.
We are always open to new talent.
News